OtherDrug Discovery and Translational Medicine
In vivo pharmacokinetic and pharmacodynamic properties of the antiarrhythmic molecule ent-verticilide
Daniel J Blackwell, Abigail N Smith, Tri Q. Do, Aaron Gochman, Jeffrey Schmeckpeper, Corey R. Hopkins, Wendell S Akers, Jeffrey N Johnston and Bjorn Knollmann
Journal of Pharmacology and Experimental Therapeutics March 9, 2023, JPET-AR-2022-001455; DOI: https://doi.org/10.1124/jpet.122.001455
Daniel J Blackwell
1Medicine, Vanderbilt University Medical School, United States
Abigail N Smith
2Vanderbilt University, United States
Tri Q. Do
3Lipscomb University, United States
Aaron Gochman
4Vanderbilt University Medical Center, United States
Jeffrey Schmeckpeper
4Vanderbilt University Medical Center, United States
Corey R. Hopkins
5Pharmaceutical Sciences, University of Nebraska Medical Center, United States
Wendell S Akers
3Lipscomb University, United States
Jeffrey N Johnston
2Vanderbilt University, United States
Bjorn Knollmann
4Vanderbilt University Medical Center, United States
Jump to comment:
No eLetters have been published for this article.
In this issue
OtherDrug Discovery and Translational Medicine
PK/PD relationship of RyR2 inhibitor ent-verticilide
Daniel J Blackwell, Abigail N Smith, Tri Q. Do, Aaron Gochman, Jeffrey Schmeckpeper, Corey R. Hopkins, Wendell S Akers, Jeffrey N Johnston and Bjorn Knollmann
Journal of Pharmacology and Experimental Therapeutics March 9, 2023, JPET-AR-2022-001455; DOI: https://doi.org/10.1124/jpet.122.001455
OtherDrug Discovery and Translational Medicine
PK/PD relationship of RyR2 inhibitor ent-verticilide
Daniel J Blackwell, Abigail N Smith, Tri Q. Do, Aaron Gochman, Jeffrey Schmeckpeper, Corey R. Hopkins, Wendell S Akers, Jeffrey N Johnston and Bjorn Knollmann
Journal of Pharmacology and Experimental Therapeutics March 9, 2023, JPET-AR-2022-001455; DOI: https://doi.org/10.1124/jpet.122.001455
Jump to section
Related Articles
Cited By...
More in this TOC Section
Similar Articles
Advertisement